Skip to main content

California-based Perfect Day has devised and patented a technique for making milk-type proteins from yeast cells to make yogurt, cheese and animal-free milk.

MartinPrague

Sometimes investment opportunities appear in the strangest places. For example: yeast.

Yeast, of all things! We use it to bake bread, brew beer and make wine, and have been doing so for centuries. Nothing new here.

Except there is. No one is paying much attention yet, but several companies are looking to disrupt the traditional food chain by creating a range of yeast-based products.

Story continues below advertisement

For example, a small company in California called Perfect Day has devised and patented a technique for making milk-type proteins from yeast cells. These would then be used in the production of such dairy staples as yogurt, cheese and, yes, even animal-free milk.

“We’re creating a better way to make dairy proteins – the same nutritious proteins found in cow’s milk. And we’re doing it without the help of a single cow,” the company says on its website. “Our dairy proteins are the perfect base for dairy foods, ensuring the same delicious taste and texture – and with less impact on the earth.”

If these folks ever hit it big, bid farewell to supply management and to dairy trade disputes with the United States or anyone else.

Perfect Day is not alone in looking to yeast as a source of protein-based substitutes for a wide variety of products. Lesaffre, a large French company, is exploring the uses of the micro-organism in the creation of a wide range of food products that it says will provide “natural food flavors that reveal tastes and aromas … [and] optimize nutritional and sensory qualities.”

Lesaffre is also looking well beyond human food to expand its business. Cosmetics, perfume, pharmaceuticals and agri-foodstuffs are among the other businesses it is targeting.

“Suitable for an infinite variety of applications, our innovative product lines cover the needs of those working in the fields of human, plant and animal nutrition, and health care. Each of the developments initiated by Lesaffre targets the same core issue: helping to better protect and nourish the planet, in an environmentally-friendly manner,” the company’s website says.

Lesaffre is the largest company that is primarily devoted to developing new products from yeast and yeast extracts, but it is not publicly traded.

Story continues below advertisement

But Archer Daniels Midland is listed on the New York Stock Exchange under the symbol ADM. The company has entered into a joint venture with Lesaffre and is a leader in the use of yeast to develop a range of animal feeds.

Headquartered in Chicago, ADM is one of the world’s largest agricultural processors and food ingredient providers. It has approximately 31,000 employees serving customers in more than 170 countries. It has approximately 500 crop procurement locations, 270 ingredient manufacturing facilities, 44 innovation centres and an extensive crop transportation network.

When it comes to experimenting with yeast-based products, the company is not as ambitious as Lesaffre when it comes to expanding the range of yeast-based products for human consumption – at least not publicly. But it has developed and is actively marketing several foodstuffs for pet and livestock consumption.

One of them is CitriStim, a feed ingredient for livestock, equine, poultry, aquaculture and companion animals that is produced in a facility in North Carolina.

In 2016, ADM announced the launch of Proplex DY, a high-quality protein source for swine nursery diets. It was developed to fill a need for a quality protein source with low anti-nutritional properties to help nutrient absorption and animal growth. Proplex DY is composed of dried Saccharomyces yeast (non-active yeast), which is a source of highly digestible amino acids “that yield economic and nutritional benefits to swine, poultry and aquaculture diets.”

Earlier this year, ADM’s Animal Nutrition division announced the launch of Versity, a yeast protein food for dogs and cats. The company describes Versity as “a highly palatable dried yeast alternative to traditional plant and animal proteins that delivers a balanced profile of essential amino acids with low levels of fat and calcium.”

Story continues below advertisement

Animal Nutrition technical manager Gary Davenport said: “Pet food and treat manufacturers are continuously seeking new protein ingredients that are high-quality, cost-effective and label-friendly. Versity has an amino acid profile similar to an egg, but at a more economical price, making it an ideal complementary or replacement protein source for dogs and cats.”

At this point, yeast-based products are a small part of ADM’s overall business. The company produces a wide variety of foods, ranging from bakery mixes to corn syrup. It is also involved in the biofuels business, including the production of ethanol.

From a financial perspective, this is a very sound company. Second-quarter revenue was US$17.1-billion, up from US$14.9-billion in the same period last year. Net earnings were US$566-million (US$1 a share) compared with US$276-million (US$0.48 a share), although part of that gain can be attributed to U.S. tax reform. The effective tax rate for the quarter was 13 per cent, down from 28 per cent in 2017.

The stock pays a quarterly dividend of US$0.335 (US$1.34 a year) to yield 2.7 per cent at the current price.

The stock closed Friday at $49.31. Ask your financial adviser if it is right for your portfolio.

Gordon Pape is Editor and Publisher of the Internet Wealth Builder and Income Investor newsletters.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter